- Three BGI Researchers Listed as Highly Cited Researchers
- China National GeneBank and Macquarie University Deepen Cooperation in Synthetic Biology
- Dr. Ren Wang, Senior Vice President of BGI Attended International Symposium on Agricultural Innovation for Family Farmers
- Successful Completion of China-Africa Public Health Training Program at CNGB
- Establishment of the first Macaca fascicularis gut microbiome gene catalog
- Establishing the first gene catalogue of Sprague-Dawley rat gut metagenome based on the BGISEQ-500 platform
- The international Sc2.0 Project is on track to build the world’s first synthetic yeast genome
- Avian-specific conserved genomic elements play important regulatory roles in the macroevolution of avian-specific features
- Leading Health Organizations in Canada and China Teaming up to Accelerate Precision Medicine
- World’s largest genomic organisation to collaborate with leading Queensland researchers
- Ranomics Partners with BGI to Classify Variants of Unknown Significance
- BGI and UW collaborate on precision medicine development
- Meet The Chinese Company That Wants To Be The Intel Of Personalized Medicine
- Chinese innovation : BGI’s code for success
- Prof. Huanming Yang to Receive Membership from Royal Danish Academy of Sciences and Letters
- UW, Chinese genomics group forge new partnership to advance biomedical research
Tel: +86-755-36307212Email: firstname.lastname@example.org
On September 26, 2018, BGI and Maxwell Plus executed a collaborative research project “A model to predict the risk of developing advanced or metastatic prostate cancer using genetic makeup and family history of cancers”.
Prostate cancer is the second most common type of cancer among males in Western countries, with an estimated 165,000 new cases and 29,500 cancer deaths in 2018 alone. The objective of the project is to understand the genetic makeup of prostate cancer patients and understand how significant the association is between the prevalence of prostate, breast, ovarian and colorectal cancers in the families of patients. The risk of the genetic makeup and family history will be combined into a risk model for predicting advanced or metastatic prostate cancer. All samples will be sequenced on the cutting-edge BGI genetic sequencer, MGISEQ-2000, in the BGI Australia laboratory.
“The combination of AI (artificial intelligence) and genetic sequencing data promises to be an exciting step forward in the management of prostate cancer; we are delighted to be working with the innovative and dedicated team at Maxwell Plus”, said Dr. Lynn Fink, Research Director of BGI Australia.
"We are excited at the opportunities this collaboration brings. At Maxwell Plus we know that better patient outcomes will arise through an analysis of all of a patient's data and sequencing is and will continue to be a key part of that data.", said Dr. Elliot Smith, CEO of Maxwell Plus.
Founded in 2016, Maxwell Plus is a growing Brisbane-based medical technology start-up rethinking the way disease is detected and diagnosed by combining machine learning with complex medical data the team is working to make cancer diagnosis faster, more affordable and more accurate. More information about Maxwell Plus is available at https://maxwellplus.com/
BGI is the largest organization in the world in genomics research and applications. Since the BGI Australia office opened in 2016, BGI has initiated projects covering a wide range of areas via partnerships with strong local scientific research partners, such as imaging and genomics cancer, infectious disease, marine biology, and biodiversity. More information about BGI Australia is available at https://bgi-australia.com.au/
+61 7 3362 0475
+61 401 861 307